Rehmann Capital Advisory Group Has $4.01 Million Stake in Eli Lilly and Company (NYSE:LLY)

Rehmann Capital Advisory Group boosted its stake in Eli Lilly and Company (NYSE:LLY) by 12.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 4,849 shares of the company’s stock after buying an additional 538 shares during the period. Rehmann Capital Advisory Group’s holdings in Eli Lilly and Company were worth $4,006,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of LLY. GAMMA Investing LLC raised its holdings in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $8,407,908,000. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares in the last quarter. Capital International Investors increased its position in shares of Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company’s stock valued at $6,740,272,000 after buying an additional 1,645,222 shares during the period. Finally, Capital Research Global Investors grew its position in Eli Lilly and Company by 16.1% during the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company’s stock valued at $8,304,811,000 after acquiring an additional 1,493,673 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.7%

Eli Lilly and Company stock opened at $777.92 on Wednesday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The business has a 50 day moving average price of $769.37 and a two-hundred day moving average price of $800.14. The stock has a market cap of $737.27 billion, a price-to-earnings ratio of 63.30, a price-to-earnings-growth ratio of 1.13 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 earnings per share. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Guggenheim restated a “buy” rating and issued a $936.00 price target on shares of Eli Lilly and Company in a research note on Friday, June 20th. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Finally, HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.